02500 VENUS MEDTECH-B
- 5.620
- 0.0000.00%
VENUS MEDTECH-B News
Qiming Medical-B (2500.HK): TAVR's business has clearly recovered and overseas markets continue to expand
Qiming Healthcare (02500.HK): Results for the first half of the year were in line with expectations of domestic emissions and overseas progress
VENUS MEDTECH(2500.HK):TOPLINE IN-LINE;FOCUSING MORE ON OVERSEAS OPPORTUNITIES BOOSTS R&D EXPENSES
Qiming Healthcare (2500.HK): Domestic business emphasizes profitability, 1H23 subsidy amount declined; overseas markets rapidly expanded through VENUS-P
Qiming Medical-B (2500.HK): TAVR's continuous restoration and internationalization process continues to advance
Changes in Hong Kong stocks | Kaiming Medical-B (02500) rose more than 7% in early trading, China's leading heart valve intervention agency gave a “buy” rating
Qiming Medical (2500.HK): China's leading heart valve intervention covers all four valves in one
Qiming Medical-B (2500.HK): The recovery of TAVR business and the launch of the research pipeline highlight long-term competitive advantage
Qiming Medical-B (2500.HK): TAVR restoration sets sail for internationalization
Qiming Medical-B (2500.HK): China's TAVR pioneer draws a structural blueprint
Qiming Medical-B (2500.HK): 2022 H1 surgery volume was affected by the epidemic and research pipeline consolidates long-term competitive advantage
Qiming Medical-H (02500.HK): Performance falls short of expectations and focuses on monetization and internationalization strategies
Qiming Medical-B (2500.HK): Minutes of the company's online roadshow meeting in June 2022
Qiming Medical-B (2500.HK): VENUSP-VALVE's R&D pipeline approved for listing in Europe continues to advance
Qiming Medical-B (2500.HK): TAVR product sales lead self-research+mergers and acquisitions expand pipeline layout
Qiming Healthcare (02500.HK): TAVR's rapid growth can be expected in the future
Qiming Medical-B (2500.HK): TAVR product sales lead self-research+mergers and acquisitions expand pipeline layout
Qiming Medical-H (02500.HK): Maintaining TAVR's leading position and continuing to cultivate the field of structural thinking
Qiming Medical (02500.HK): Third-generation valves successfully joined the valve pipeline further
Qiming Medical (02500.HK): overseas acquisition of CARDIOVALVE enriches mitral and tricuspid valve layout
No Data
